NCT07234422 The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
| NCT ID | NCT07234422 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Netherlands Heart Institute |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,100 participants |
| Start Date | 2026-05-04 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,100 participants in total. It began in 2026-05-04 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease. Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes. Participants will: Receive either selenium-CoQ10 or placebo in addition to their usual heart failure treatment Attend standard clinical visits according to routine clinical care. The study will include 1,100 adults with chronic heart failure. Selenium and CoQ10 are natural nutrients with no known health risks. If effective, this supplement could provide a safe new way to improve outcomes for people with heart failure.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * Outpatients with chronic HF, NYHA II - ambulatory IV * Serum NT-proBNP concentrations \>600 pg/mL (71 pmol/L) if in sinus rhythm; \>1000pg/mL (118 pmol/L) if in Atrial fibrillation\* Exclusion Criteria: * History of myocardial infarction, myocarditis, percutaneous intervention, cardiac surgery or stroke \<30 days * The presence of a mechanical assist device * Scheduled for mechanical assist device or heart transplant * Other non-cardiac conditions with limited life expectancy (\<1 year) * Amyloid, hypertrophic obstructive or constrictive cardiomyopathy * End stage kidney disease for which chronic intermittent peritoneal or haemodialysis * Unable to sign informed consent * (Unwilling to stop) use of over the counter supplements coQ10/selenium * Peanut and/or soy allergy
Contact & Investigator
Peter van der Meer, prof dr
PRINCIPAL INVESTIGATOR
University Medical Center Groningen
Frequently Asked Questions
Who can join the NCT07234422 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07234422 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,100 participants.
Is NCT07234422 currently recruiting?
Yes, NCT07234422 is actively recruiting participants. Contact the research team at seleqt-hf@umcg.nl for enrollment information.
Where is the NCT07234422 trial being conducted?
This trial is being conducted at Alkmaar, Netherlands, Amsterdam, Netherlands, Breda, Netherlands, Eindhoven, Netherlands and 3 additional locations.
Who is sponsoring the NCT07234422 clinical trial?
NCT07234422 is sponsored by Netherlands Heart Institute. The principal investigator is Peter van der Meer, prof dr at University Medical Center Groningen. The trial plans to enroll 1,100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.